Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites
Status:
Not yet recruiting
Trial end date:
2025-03-20
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic
virotherapy combined with Tislelizumab for patients with refractory malignant ascites.